A new book by Hedley Rees tackles a litany of pharma industry problems, including “eye-watering drug prices, shortages, litigation over damaging side effects, questionable marketing practices, economic adulteration, consent decrees, counterfeiting, patent games [and] price gouging”.
Rees says we should stop believing that medicines are different to all other products on sale in the market, because they are not. Science is an important component in bringing a medicine to the world, but it takes a healthy dose of engineering skills to get them there too, and the application of those skills is sadly lacking in pharma. The system for producing and supplying a medicine to market should be no different, he says, to an aero-engine, automobile or silicon chip. While the book is “uncompromising on facts and evidence”, it aims to offer a “practical solution” for the pharma industry, says the author. Taming The Big Pharma Monster by Speaking Truth to Power by Hedley Rees is published by Filament (London) on May 28, 2019. More information can be found at the author's website: pharmaflowltd.com
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.